g dL

Related by string. GDLS * Gd . Ger . GED . GD . GS . gd . G. . G . GER . gs . Gs : g t gold . g t Ag . John G. Rowland . g t silver . Goldman Sachs nyse GS . b g . G irls . Allen G. Breed . g t Au . G eorge . #.#b g Wi Fi / DLS . dl . DLD . DLs . Dl . ding ling . DL . Ding Ling . dling . Ding ling : Yard Freestyle =-#.# mg dL . DL Calarco Funeral Home . DL stint . ng dL . -#.# mg dL [002] . -#.# mg dL [001] . mg dL . DL Ravindra Reddy . ng dl . mg dl * *

Related by context. All words. (Click for frequent words.) 74 g dl 72 mg dL 72 ng mL 70 ng dL 69 mmol L 68 ng ml 67 pg mL 67 mg dl 66 nmol L 66 mg d 66 mEq L 66 mmol l 65 nmol liter 64 μg dL 64 mL/min/#.# m 2 64 sUA 64 pg ml 64 mcg mL 64 baseline HbA1c 64 HbA 1c levels 64 HbA1c levels 63 Hb A1C 63 mIU L 63 creatinine clearance 63 serum phosphorus 63 μg L 63 mmHg 63 confidence interval CI 63 μmol L 62 mm Hg 62 #mg/dL [001] 62 #.#mg/dL 62 mg kg Hematide 62 HbA1c 62 pmol L 62 lumbar spine BMD 62 log# copies mL 61 HbA 1c 61 mU L 61 mcg kg 61 HBeAg seroconversion 61 hemoglobin concentrations 61 mg kg 61 -#.# mg dL [002] 61 #mg/dL [002] 61 % CI #.#-#.# [006] 61 QTcF 61 LVEF 61 Cmax 61 ug kg 60 % Confidence Interval 60 #mmHg [001] 60 copies mL 60 achieved ACR# 60 Hb 60 % CI #.#-#.# [003] 60 cells/mm3 60 Hb levels 60 statistical significance p 60 A1c levels 60 sd = 60 CrCl 60 Median survival 60 log# 60 P = .# 60 sUA levels 60 virologic failure 60 median PFS 60 pmol liter 60 p = NS 59 x ULN 59 severe renal impairment 59 p = 59 hemoglobin A1c HbA1c 59 ng dl 59 eGFR 59 mL/min/#.# m2 59 mL min 59 alanine aminotransferase 59 mIU ml 59 copies ml 59 serum creatinine levels 59 per deciliter mg 59 ml kg 59 IU mL 59 interquartile range 59 IU ml 59 creatinine ratio 59 mg kg dose 59 undetectable HCV RNA 59 -#.# log# 59 p = #.# [002] 59 recurrent VTE 59 nanograms per 59 #.#/#.# mmHg [001] 59 MADRS score 59 serum uric acid 58 mIU mL 58 PSA nadir 58 undetectable viral load 58 mm Hg systolic 58 hemoglobin levels 58 nondiabetic patients 58 mcg dL 58 definite stent thrombosis 58 lispro 58 kg/m2 58 postintervention 58 leukopenia 58 CI -#.# 58 oxycodone CR 58 lopinavir r arm 58 nonobese 58 NNT = 58 CK MB 58 #mmHg [002] 58 % CI #.#-#.# [002] 58 reinfarction 58 mU liter 58 mmol L. 58 mg ustekinumab 58 HbA1C levels 58 certolizumab 58 hemoglobin concentration 58 serum phosphorus levels 58 insulin detemir 58 biochemical relapse 58 mg BID 58 glycated hemoglobin HbA1c 58 #.#mmol l [002] 58 NATRECOR R 58 CDAI score 58 plasma concentrations 57 systolic BP 57 gm dL 57 serum sodium 57 mmHg diastolic 57 #mg/kg [002] 57 serum potassium 57 placebo p = 57 nmol l 57 μg 57 mean baseline HbA1c 57 #mg/dl 57 Hb A1c 57 serum calcium 57 CR nPR 57 mg 57 unfractionated heparin 57 glycated hemoglobin levels 57 anemia hemoglobin 57 μg kg 57 binary restenosis 57 transferrin saturation 57 mcg 57 REYATAZ r arm 57 leukocyte count 57 placebo p 57 nonfatal MI 57 PASI scores 57 n = 57 cGy 57 serum creatinine 57 mg QD 57 alanine aminotransferase ALT 57 serum testosterone 57 serum phosphate levels 57 serum urate 57 neutrophil counts 57 #.#mmol L [002] 57 microg 57 mCi m 2 57 mmol liter 57 umol L 57 biochemical recurrence 57 normal ULN 57 baseline Hb 57 #mg/day [002] 57 A1C levels 57 log# IU mL 57 hours postdose 57 #mg/day [001] 57 moderate renal impairment 57 #.#mmol L [001] 57 μg liter 57 hsCRP levels 57 #ng/ml 56 PREZISTA r arm 56 noninferiority 56 HbA1C 56 diastolic blood pressures 56 thromboembolic events 56 iPTH 56 μg ml 56 serum ALT 56 EDSS score 56 log# reduction 56 statistically significant p = 56 cells uL 56 gastric pH 56 periprocedural 56 nmol L. 56 Baseline characteristics 56 hydroxyvitamin D levels 56 hemoglobin Hb 56 % CI #.#-#.# [007] 56 CI = 56 systemic embolism 56 plasma HCV RNA 56 comparator arm 56 fasting triglyceride levels 56 glycated hemoglobin 56 serum concentrations 56 seroconversion 56 μg mL 56 severe neutropenia 56 per deciliter 56 nonfasting triglyceride levels 56 serum aminotransferase levels 56 preintervention 56 serum IGF 56 fraction LVEF 56 mg Lucentis 56 p = .# [002] 56 CI #.#-#.# [001] 56 NPH insulin 56 mg dose 56 FEV1 56 CD4 + cell 56 progression TTP 56 CsA 56 mcg albinterferon alfa 2b 56 Hgb 56 #.#ng/ml 56 low dose Iluvien 56 epoetin alfa 56 mcg BID 55 virologic response 55 baseline serum creatinine 55 OADs 55 evaluable subjects 55 tirofiban 55 mmHg p = 55 4mg/kg 55 1c HbA 1c 55 Operative mortality 55 hematologic toxicity 55 febrile neutropenia 55 diastolic BP 55 oral allopurinol 55 OGTT 55 annualized relapse 55 GnRH agonist 55 glomerular filtration rate 55 abacavir lamivudine 55 prespecified 55 hypokalemia 55 aspartate aminotransferase 55 serum phosphate 55 adefovir treated 55 mm Hg diastolic 55 hemoglobin A1c levels 55 creatinine levels 55 mg/m2 dose 55 urate lowering therapy 55 mmHg systolic 55 ipsilateral stroke 55 prehypertensive 55 placebo 55 gm dl 55 baseline A1C 55 microgram kg 55 adjunctive placebo 55 ALT elevation 55 % CI #.#-#.# [008] 55 X ULN 55 aspartate aminotransferase AST 55 elevated transaminases 55 baseline CD4 55 fasting plasma glucose FPG 55 non inferiority 55 pegylated interferon alfa 2b 55 arterial thromboembolic events 55 mg m 55 antibody titer 55 highest tertile 55 plasma glucose levels 55 coronary revascularization 55 μg dose 55 fosamprenavir 55 LPV r 55 transaminase elevations 55 dapagliflozin plus 55 mcg dose 55 PREZISTA r 55 HCV RNA 55 μg dl 55 repeat revascularization 55 normotensive 55 cells μL 55 IIIa inhibitors 55 ARCOXIA 55 nonsignificant 55 statin monotherapy 55 #mm Hg 55 tumor recurrence 55 urine albumin 55 peginterferon alfa 2a 55 ± 55 EDSS scores 55 insulin glargine 55 BENICAR HCT 55 Median PFS 55 REMICADE monotherapy 55 MMSE score 54 μg d 54 serum potassium levels 54 ALT flares 54 Viread Emtriva Sustiva 54 posttreatment 54 #OHD levels 54 mg m² 54 ACR# response 54 mL sec 54 ug dl 54 timepoint 54 endoscopic remission 54 aged ≥ 54 nmol 54 elevated creatinine 54 p = #.# [004] 54 statistically significant p 54 detectable HCV RNA 54 Lucentis monotherapy 54 nanograms milliliter 54 IPSS 54 PaO 2 54 troponin T 54 ± SD 54 % CI #.#-#.# [004] 54 confidence interval #.#-#.# 54 Platelet counts 54 microalbuminuria 54 aminotransferases 54 pT3 54 TAXUS p value 54 milligrams mg 54 #mg BID [001] 54 #.#/#.# mm Hg [003] 54 experienced virologic failure 54 glulisine 54 peginterferon alfa 2b 54 poor metabolizers 54 lopinavir r 54 nondiabetics 54 tertile 54 tapentadol ER 54 oxycodone IR 54 plasma urate 54 lactate dehydrogenase LDH 54 tacrolimus 54 creatinine 54 ertapenem 54 dalteparin 54 detemir 54 MELD scores 54 Pred Forte 54 -#.# ± [002] 54 5-FU/LV 54 mg/m2/day 54 rapid virologic response 54 KDOQI 54 evaluable 54 aminotransferase levels 54 mCi kg 54 #mg BID [003] 54 sirolimus stent 54 mmol 54 hip BMD 54 severe hypoglycemic 54 proteinuria 54 revascularization procedures 54 severe exacerbations 54 cerebrovascular events 54 μg l 54 mg orally 54 Complication rates 54 specific antigen PSA 54 HBeAg negative patients 54 transaminases 54 macroalbuminuria 54 FOLFOX4 54 glycosylated hemoglobin HbA1c 54 SCr 54 antibody titers 54 infliximab monotherapy 54 elevated LDH 54 mcg Albuferon 54 advanced adenomas 54 tipranavir r 54 elevated ALT 54 μmol l 54 subclinical hypothyroidism 54 ug ml 54 perioperative complications 54 placebo dexamethasone 54 amoxicillin clavulanate 54 XIENCE V PROMUS Stent 54 rizatriptan 54 mg TID 54 mg simvastatin 54 Serum creatinine 54 aldosterone antagonist 54 Ishak fibrosis score 54 CCyR 53 NovoLog ® Mix 53 baseline LDH 53 A1C 53 corticosteroid dose 53 IOP lowering 53 nicardipine 53 receiving ISENTRESS 53 hypophosphatemia 53 tHcy 53 cardiovascular hospitalizations 53 undetectable HBV DNA 53 BMI ≥ 53 cells mcL 53 -#.# ± [001] 53 lowest tertile 53 â ‰ ¥ 53 SELENA SLEDAI score 53 refractory ischemia 53 Index CDAI score 53 53 primary hypercholesterolemia 53 atorvastatin #mg 53 Q2W 53 hepatorenal syndrome 53 achieved statistical significance 53 hyperphenylalaninemia HPA due 53 serum phosphorous 53 serum albumin 53 APTIVUS r 53 A1c 53 RBC transfusions 53 thyrotropin levels 53 platelet reactivity 53 PREZISTA ritonavir 53 plasma uric acid 53 micrograms mL 53 mean baseline A1C 53 MACCE 53 hypogonadal men 53 enoxaparin 53 TEAEs 53 postoperative mortality 53 saline placebo 53 per decilitre 53 HOMA IR 53 UACR 53 NCEP ATP III 53 LS BMD 53 ATACAND 53 pCR 53 HIV RNA 53 #mg QD [002] 53 nonfatal myocardial infarction 53 ml min 53 homocysteine concentrations 53 fragility fracture 53 intima media thickness 53 median CD4 53 lanthanum carbonate 53 MMSE scores 53 serum urate levels 53 ARIXTRA 53 adefovir 53 DAS# [002] 53 metastatic GIST 53 vaginal hysterectomy 53 chlorambucil 53 mL kg 53 endometrial thickness 53 #/#mmHg 53 serum HBV DNA 53 thromboprophylaxis 53 ACR# responses 53 vertebral fracture 53 gestational hypertension 53 BARACLUDE ® 53 HAM D# scores 53 fasting blood glucose 53 mcg kg min 53 vaccinees 53 HER2 expression 53 #.#mg/kg [002] 53 mg/m2 53 CDAI 53 Primary endpoints 53 NATRECOR ® 53 QTc 53 intact parathyroid hormone 53 blood Phe 53 serum calcium levels 53 nM 53 Crohn Disease Activity 53 viral load 53 crossclamp 53 infarct size 53 postdischarge 53 Hazard Ratio = 53 postoperatively 53 seroprotection 53 PSADT 52 -#.# mg dL [001] 52 ug mL 52 octreotide LAR 52 deciliter 52 ALND 52 serum estradiol 52 FluCAM arm 52 postmenopausal osteoporotic women 52 #.#mmHg 52 mcg QD 52 neurodevelopmental impairment 52 β blockers 52 postprocedure 52 IQR = 52 #-# mg dL 52 darbepoetin alfa 52 symptomatic intracranial hemorrhage 52 RBC transfusion 52 timepoints 52 cardiovascular mortality 52 ug dL 52 confidence intervals CIs 52 neutrophil count 52 blood Phe levels 52 #OHD 52 prior nephrectomy 52 anticoagulation therapy 52 HbA 1C 52 piperacillin tazobactam 52 elevated serum creatinine 52 pulmonary exacerbations 52 Flu Cy 52 left ventricular systolic 52 hematologic adverse 52 concomitant medications 52 PASI score 52 splenectomized 52 p = .# [001] 52 Psoriasis Area 52 CK # plasma 52 thyroglobulin 52 kg m² 52 CVD mortality 52 diameter stenosis 52 SGPT 52 #mg/m# [001] 52 prolonged QT interval 52 nonfatal stroke 52 plasma folate 52 titrated glipizide 52 % CI #.#-#.# [001] 52 HSCT 52 retinal thickness 52 recurrent wheezing 52 myocardial infarction stroke 52 Index CDAI 52 Fasting blood glucose 52 hematocrit 52 mg qd 52 apnea hypopnea index 52 LANTUS R 52 CI #.#-#.# [002] 52 reintervention 52 nonpregnant women 52 discontinuations due 52 hypocalcemia 52 FOLPI 52 posaconazole 52 atazanavir ritonavir 52 estimated glomerular filtration 52 euthyroid 52 seropositivity 52 Kaplan Meier analysis 52 Peg IFN 52 DES implantation 52 serum glucose 52 IQR 52 oral antidiabetic medication 52 recurrent venous thromboembolism 52 ximelagatran 52 Non inferiority 52 EXJADE 52 sustained virological response 52 systolic dysfunction 52 lamivudine monotherapy 52 dose cytarabine 52 advanced adenoma 52 mU 52 beta blocker therapy 52 lymphocyte count 52 dose colchicine 52 morphometric vertebral fractures 52 HBeAg negative 52 clodronate 52 chronic hemodialysis 52 postop 52 rapid virological response 52 thrombocytopenia 52 3mg/kg 52 asymptomatic carotid stenosis 52 ejection fractions 52 adjunctive ABILIFY 52 ritonavir boosted lopinavir 52 undergoing coronary angiography 52 mean serum phosphorus 52 recurrent ischemia 52 azacitidine 52 subtrochanteric 52 HBV DNA levels 52 underwent resection 52 lymphocytosis 52 anti HBs 52 oral prednisone 52 Acetate Rectal Suppositories 52 Gy 52 transaminase elevations greater 52 serum HCV RNA 52 baseline FEV 52 composite endpoint 52 renal dysfunction 52 uM 52 fasting triglycerides 52 splenectomized patients 52 pg g 52 evaluable patients 52 aminotransferase elevations greater 52 EBRT 52 deep venous thromboses 52 intramuscularly 52 unfractionated heparin UFH 52 XIENCE V vs. 52 atheroma volume 52 ribavirin therapy 52 plus dexamethasone 52 HES CEL 52 degarelix 52 PNH patients 52 lipid lowering therapy 52 IIIa inhibitor 52 patients undergoing CABG 52 irbesartan 52 events MACE 52 fasting insulin 52 urinary N telopeptide 52 platelet counts 52 cTnT levels 52 FOLFIRI alone 52 #mg BID [002] 52 imipenem 52 GPIIb IIIa inhibitors 52 renal insufficiency 52 laboratory abnormalities 52 serum magnesium 52 flutamide 52 mm3 52 NYHA class 52 clopidogrel 52 mg kg hr 52 myocardial infarction MI 52 Fasting plasma glucose 52 mild renal insufficiency 51 glargine 51 mg/m2 IV 51 CRESTOR #mg 51 #.#/#.# mm Hg [001] 51 systemic corticosteroids 51 endarterectomy 51 micrograms mcg 51 BLLs 51 HI titers 51 plus methotrexate 51 + PH# 51 PROCTOCORT ® Suppository Hydrocortisone 51 PRADAXA #mg 51 β blocker 51 sinus rhythm 51 bone marrow reticulin 51 Hazard Ratio 51 univariate analysis 51 fatal myocardial infarction 51 CIMZIA TM 51 DAPT 51 perioperative mortality 51 8mg/kg 51 genotypic resistance 51 orchiectomy 51 LEXIVA r 51 hypopneas 51 statistically significant 51 SHBG levels 51 nondrinkers 51 dacarbazine 51 glycosylated hemoglobin 51 p = #.# [003] 51 FOLFOX 51 Calcium intake 51 ATV RTV 51 parous women 51 serum bilirubin 51 mg kg bw 51 sham injections 51 dose cohort 51 doxorubicin docetaxel 51 GH deficiency 51 NHANES III 51 anthracycline taxane 51 achieved PASI 51 pooled comparator 51 receiving prophylactic anticoagulation 51 recurrent atrial fibrillation 51 estimated GFR 51 serum TSH 51 mcg linaclotide 51 primary efficacy endpoint 51 transaminase 51 HIV uninfected 51 metoprolol tartrate 51 serum sodium concentration 51 RYGB 51 inhospital 51 titrated 51 FOLFOX4 alone 51 symptomatic VTE 51 SUVmax 51 #mg/m# [002] 51 efavirenz EFV 51 NIHSS 51 amprenavir 51 Elitek 51 posttransplant 51 Engerix B 51 Adverse events 51 Zometa hazard 51 micromoles 51 undetectable viral 51 budesonide pMDI 51 nadroparin 51 plus MTX 51 serum PTH 51 CNS systemic embolism 51 TORISEL 51 plasma glucose 51 MULTAQ 51 mineral density 51 nonsignificant difference 51 overt nephropathy 51 fondaparinux 51 chlorthalidone 51 subcutaneous enoxaparin 51 non splenectomized 51 TNF antagonist 51 virological failure 51 CYPHER Stent 51 intracranial hemorrhage ICH 51 NIHSS score 51 NOXAFIL Oral Suspension 51 virological response 51 quetiapine XR 51 #mg QD [001] 51 NYHA Class II 51 postoperative morbidity 51 elevated troponin 51 Viread Emtriva SUSTIVA 51 fluticasone salmeterol 51 mg tid 51 Virologic failure 51 stent thromboses 51 P ≤ 51 distant metastases 51 osteopenic 51 ABC/3TC 51 corrected QT interval 51 #ug [001] 51 plus GP IIb 51 serum prostate 51 refractory NSCLC 51 Myelosuppression 51 eplerenone 51 LAB GHRH 51 oral prednisolone 51 kcal d 51 URTI 51 coadministration 51 hypertensive patients 51 BMS p = 51 #μg [001] 51 oral hypoglycemic agents 51 cholesterol LDL C 51 transaminase levels 51 cTnI 51 micromolar 51 asthma exacerbation 51 antihypertensive medications 51 Median progression 51 glycoprotein IIb IIIa inhibitors 51 revascularizations 51 mild renal impairment 51 hemoglobin A1c 51 symptom onset 51 ULORIC 51 warfarin therapy 51 glimepiride 51 nanomoles per 51 VT VF 51 hemoglobin A1C 51 triacylglycerol concentrations 51 systemic hypotension 51 CMV disease 51 kg -1 51 #.#g/day 51 aPTT 51 mg subcutaneously 51 mCi 51 simvastatin #mg 51 plasma leptin 51 mg p = 51 Known hypersensitivity 51 mCRC patients 51 triglyceride concentration 51 glomerular filtration 51 total cholesterol LDL 51 thromboembolism 51 concomitant antibiotics 51 procalcitonin 51 tPSA 51 recurrent ischemic 51 ischemia driven 51 calculated creatinine clearance 51 hypomagnesemia 51 mm ³ 51 underwent CABG 51 serum vitamin D 51 femoral neck BMD 51 % CI #.#-#.# [005] 51 tenecteplase 51 concentration Cmax 51 placebo PBO 51 K DOQI 51 dexmedetomidine 51 PRADAXA 51 ALT elevations 51 mol L 51 #mg doses [002] 51 imatinib therapy 51 free survival PFS 50 Navelbine 50 IFN alfa 50 TDF FTC 50 serum retinol 50 preoperatively 50 HPV-#/# 50 Homocysteine levels 50 HGPIN 50 serum testosterone levels 50 Left Ventricular Ejection Fraction 50 rFVIIa 50 receiving Vectibix monotherapy 50 q#h 50 fasting plasma glucose 50 elevated LDL cholesterol 50 intravesical therapy 50 cTnT 50 severe hypoglycemia 50 anticoagulation 50 mg/# h 50 IELT 50 6MWD 50 mRCC 50 μSv 50 left ventricular ejection 50 fasting glucose 50 locoregional recurrence 50 seropositive patients 50 symptomatic intracerebral hemorrhage 50 inhibin B 50 nondepressed 50 albumin excretion 50 mcg kg REBETOL 50 pioglitazone 50 baseline neutrophil counts 50 COZAAR 50 ONGLYZA 50 mg q#h 50 oral antidiabetes 50 palivizumab 50 allogeneic SCT 50 oocytes retrieved 50 target vessel revascularization 50 Kaplan Meier estimates 50 hypogonadal 50 mcg doses 50 tamsulosin 50 decitabine 50 mg/# hr 50 -#.# log# copies mL 50 thromboembolic 50 milligrams deciliter 50 milliliters mL 50 ULN 50 fasting glucose levels 50 thrombotic events 50 MIC# [001] 50 oral diclofenac 50 tertiles 50 hypoglycemic events 50 creatinine clearance CrCl 50 microliter 50 Pharmacokinetic parameters 50 HBeAg 50 Folfox 50 viremia 50 statistically significant reduction 50 receiving APTIVUS r 50 odds ratios ORs 50 mL 50 bolus dose 50 plus medroxyprogesterone acetate 50 Fasting glucose 50 adiponectin concentrations 50 nocturnal hypoglycaemia 50 reduce serum phosphate 50 ischemic cardiomyopathy 50 polyp recurrence 50 placebo fluoxetine 50 adalimumab 50 ECOG PS 50 active comparator 50 low dose cytarabine 50 elevated uric acid 50 cm flux 50 fluorouracil 50 neoadjuvant HT 50 generalized edema 50 Kidney Int 50 #ug [002] 50 Viread Emtriva 50 cilostazol 50 doxorubicin cyclophosphamide 50 hydroxyvitamin D 50 Free Survival PFS 50 symptomatic hypotension 50 mg/# hours 50 hydroxyvitamin D concentrations 50 non splenectomised 50 mucosal healing 50 #mg dose [002] 50 mmol kg 50 hypercalcemia 50 Stent thrombosis 50 reach statistical significance 50 elevated hsCRP 50 mg eq 50 incontinence episodes 50 coronary stenosis 50 blood phenylalanine Phe 50 VELCADE melphalan 50 serum folate 50 ketorolac 50 recurrent UTI 50 mg + GLY 50 IRLS score 50 maximal doses 50 dual antiplatelet therapy 50 ABRAXANE therapy 50 mg estradiol 50 coinfected patients 50 rFSH 50 virologic failures 50 thrombocytopenic 50 abdominal adiposity 50 BENICAR 50 creatine kinase 50 plus ribavirin 50 alkaline phosphatase 50 hemorrhagic complications 50 angiographic restenosis 50 FDA defined valvulopathy 50 hemodynamically significant 50 receiving VICTRELIS 50 relapsed MM 50 cm H2O 50 oral glucose tolerance 50 pretest probability 50 EpCAM expression

Back to home page